Myeloid-derived suppressor cells as intruders and targets: clinical implications in cancer therapy

• Published in: Cancer Immunology, Immunotherapy Vol. 65; no. 7; pp. 857 - 867
• Main Author: Baniyash, Michal
• Format: Journal Article Book Review
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.07.2016; Springer Nature B.V
• Subjects: Animals; Cancer Research; Focussed Research Review; Humans; Immunology; Immunotherapy - methods; Medicine; Medicine & Public Health; Myeloid-Derived Suppressor Cells - immunology; Myeloid-Derived Suppressor Cells - pathology; Neoplasms - immunology; Neoplasms - pathology; Neoplasms - therapy; Oncology; Tumor Microenvironment - immunology; Chemotherapy; Chronic inflammation; CITIM 2015; Immunotherapy; Cancer; Immune system biomarkers
• ISSN: 0340-7004; 1432-0851
• DOI: 10.1007/s00262-016-1849-y

Chronic inflammation, typical of various diseases including cancer, is a “silent bomb within the body,” leading to complications that are only evident in most cases upon their appearance, when disease is already deteriorated. Chronic inflammation is associated with accumulation of myeloid-derived suppressor cells (MDSCs), which lead to immunosuppression. MDSCs have numerous harmful effects as they support tumor initiation, tumor growth and spreading, which in turn, perpetuate the inflammatory and suppressive conditions, thus preventing anticancer responses. As the concept of the immune system combating many types of tumors was revived in recent years, immunotherapy has dramatically changed the view of cancer treatment, and numerous novel therapies have been developed and approved by the FDA. However, cumulative clinical data point at very limited success rates. It is most likely that the developing chronic inflammation and MDSC-induced immunosuppression interfere with responses to such treatments and hence are major obstacles in achieving higher response rates to immune-based therapies. Moreover, chemotherapies were shown to have adverse immunoregulatory effects, enhancing or decreasing MDSC levels and activity, thus affecting treatment success. Therefore, therapeutic manipulations of chronic inflammation and MDSCs during cancer development are likely to enhance efficacy of immune- and chemo-based treatments, switching chronic pro-cancer inflammatory environments to an anticancerous milieu. Based on the functional relevance of immune networking in tumors, it is critical to merge monitoring immune system biomarkers into the traditional patient’s categorization and treatment regimens. This will provide new tools for clinical practice, allowing appropriate management of cancer patients toward a better-personalized medicine.